Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Accenture
Express Scripts
UBS
Chinese Patent Office
Cantor Fitzgerald
Chubb
Federal Trade Commission
Fuji

Generated: December 11, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BETRIXABAN

« Back to Dashboard

Clinical Trials for Betrixaban

Trial ID Title Status Sponsor Phase Summary
NCT00742859 Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin Completed Portola Pharmaceuticals Phase 2 Prevention of stroke in patients with atrial fibrillation (AF). Hypothesis: In patients with non-valvular AF, orally administered betrixaban will provide similar or better efficacy and safety than warfarin and it will offer the advantage of not requiring dose adjustments due to INRs outside the target range of 2.0 to 3.0 and a more consistent level of anticoagulation over time.
NCT00999336 A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment Completed Merck Sharp & Dohme Corp. Phase 1 The purpose of the study is to compare the pharmacokinetics, pharmacodynamics, and tolerability of betrixaban in patients with mild, moderate, and severe renal impairment to healthy volunteers.
NCT00999336 A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment Completed Portola Pharmaceuticals Phase 1 The purpose of the study is to compare the pharmacokinetics, pharmacodynamics, and tolerability of betrixaban in patients with mild, moderate, and severe renal impairment to healthy volunteers.
NCT01229254 Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation (Study MK-4448-006) Completed Portola Pharmaceuticals Phase 2 The primary purpose of this study is to optimize drug exposure in the target population.
NCT01229254 Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation (Study MK-4448-006) Completed Merck Sharp & Dohme Corp. Phase 2 The primary purpose of this study is to optimize drug exposure in the target population.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Betrixaban

Condition Name

Condition Name for Betrixaban
Intervention Trials
Atrial Fibrillation 2
Hepatic Impairment 1
Healthy Subjects 1
Healthy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Betrixaban
Intervention Trials
Atrial Fibrillation 2
Renal Insufficiency 1
Liver Diseases 1
Venous Thromboembolism 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Betrixaban

Trials by Country

Trials by Country for Betrixaban
Location Trials
United States 43
Canada 6
Spain 6
Australia 4
South Africa 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Betrixaban
Location Trials
California 3
Florida 3
Missouri 2
Maryland 2
Illinois 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Betrixaban

Clinical Trial Phase

Clinical Trial Phase for Betrixaban
Clinical Trial Phase Trials
Phase 3 1
Phase 2 3
Phase 1 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Betrixaban
Clinical Trial Phase Trials
Completed 7
Not yet recruiting 1
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Betrixaban

Sponsor Name

Sponsor Name for Betrixaban
Sponsor Trials
Portola Pharmaceuticals 9
Merck Sharp & Dohme Corp. 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Betrixaban
Sponsor Trials
Industry 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Dow
Moodys
Deloitte
UBS
QuintilesIMS
Federal Trade Commission
Citi
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.